| 27.13 0.13 (0.48%) | 04-17 15:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.36 | 1-year : | 38.97 |
| Resists | First : | 28.56 | Second : | 33.36 |
| Pivot price | 25.66 |
|||
| Supports | First : | 21.11 | Second : | 16.5 |
| MAs | MA(5) : | 26.7 |
MA(20) : | 25.04 |
| MA(100) : | 25.54 |
MA(250) : | 13.42 |
|
| MACD | MACD : | 0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 71.8 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 38.32 | Low : | 2.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLTO ] has closed below upper band by 9.1%. Bollinger Bands are 70.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.94 - 28.02 | 28.02 - 28.12 |
| Low: | 26.44 - 26.54 | 26.54 - 26.65 |
| Close: | 26.95 - 27.1 | 27.1 - 27.27 |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Thu, 26 Mar 2026
GLTO SEC Filings - Galecto Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sun, 15 Feb 2026
Assessing Galecto (GLTO) Valuation After Sharp Short-Term Share Price Momentum - Yahoo Finance
Wed, 11 Feb 2026
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock | GLTO Stock News - Quiver Quantitative
Tue, 10 Feb 2026
Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan
Mon, 08 Dec 2025
Galecto (GLTO) Rating Maintained by Guggenheim, Price Target Rai - GuruFocus
Mon, 10 Nov 2025
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Fundi - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 277 (K) |
| Shares Short P.Month | 169 (K) |
| EPS | -12.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.6 % |
| Return on Equity (ttm) | -109.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.25 |
| PEG Ratio | 0 |
| Price to Book value | 5.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -133.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|